Key points are not available for this paper at this time.
High-dose IL-2 treatment seems to benefit some patients with metastatic melanoma by producing durable CRs or PRs and should be considered for appropriately selected melanoma patients.
Building similarity graph...
Analyzing shared references across papers
Loading...
Michael B. Atkins
Michael T. Lotze
Janice P. Dutcher
Journal of Clinical Oncology
Novartis (Switzerland)
Building similarity graph...
Analyzing shared references across papers
Loading...
Atkins et al. (Thu,) studied this question.
www.synapsesocial.com/papers/69dcd76b93ad366770e52ed4 — DOI: https://doi.org/10.1200/jco.1999.17.7.2105
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: